PROJECT TITLE: LHD Emerging Health Threats

Readiness and Response

Start Date: 4/1/2025 End Date: 9/30/2025

Project Synopsis:

The purpose of this project is to support LHDs' ability to assess risk and prepare communities for emerging health threats impacting their jurisdiction. The funding can be used for targeted outreach to vulnerable communities and to support response to measles cases, to address emerging environmental health threats, and to educate the community and prepare for the fall 2025 respiratory season. Funding is intended primarily to support staff time.

Purchase of vaccine is allowed with this grant if MMR, influenza, and/or COVID vaccine is not otherwise available in the jurisdiction. Purchase of immunoglobulin is **not** allowed.

Allowable expenditures include but are not limited to:

- Staff time, temporary staff time, overtime for off-hours including evenings, weekends, and holidays,
- Costs associated with data analysis.
- Outreach to vulnerable communities, including communications and health education,
- Immunization appointments and clinics, community vaccination costs, and clinic supplies and materials.
- Support of <u>measles</u> cases or contacts with isolation, quarantine, and accessing postexposure prophylaxis – if necessary,
- Costs associated with response to new and emerging environmental health threats not already funded (**not for existing PFAS projects**),
- Costs associated with vector borne surveillance and education (i.e. Eastern Equine Encephalitis, etc.).
- Costs associated with tuberculosis cases and related follow up.

This funding will be used for any new PFAS and/or vapor intrusion projects identified after May 13, 2025 through September 30, 2025.

Funding may not be used for capital improvements or purchase of vehicles.

Reporting Requirements (if different than agreement language):

- Notify MDHHS of any measles cases under investigation (via regional epidemiologist).
- Share press releases on measles cases or exposures with the MDHHS PIO and your regional epidemiologist.
- Completion of measles case report forms in MDSS.
- Results of symptom monitoring reported via the Outbreak Management System (OMS) for measles.
- For reporting related to PFAS sites see existing PFAS Attachment III (available on EGrAMS home page under the Comprehensive Agreement).
- Completion of a survey tool at the conclusion of FY25 to identify which emerging health threats were addressed using this funding, as well as cost by individual PFAS and/or vapor intrusion sites.

Any additional requirements (if applicable):